Figure 1. Anti-β₂M mAbs and BTZ combination treatment in MM cells.

10 μg/mL anti-β₂M mAbs were combined with various concentrations of BTZ in ARP-1. (A) and MM.1S (B) cells. 5 nM BTZ combined with various concentrations of anti-β₂M mAbs in ARP-1 (C) and MM.1S (D) cells. (E) Anti-β₂M mAbs combined with BTZ in different MM cell lines. (F) Anti-β₂M mAbs combined with BTZ in CD138⁺ patient (Pt) MM cells isolated from three BTZ-sensitive MM patients and two BTZ-resistant (BR) MM patients. After 24 hours of treatment, cell apoptosis was monitored by annexin-V binding assay. In E and F, 5 nM BTZ and 10 μg/mL anti-β₂M mAbs was used. Summarized data from three independent experiments are shown. **P < 0.01.